Rybelsus (semaglutide) is an oral GLP-1 receptor agonist used to manage type 2 diabetes. Some patients report changes in urine odour whilst taking this medication, though no official link is established in UK regulatory guidance. Alterations in urine smell are more commonly attributed to dehydration from gastrointestinal side effects, dietary changes, or unrelated factors such as urinary tract infections. Understanding the potential causes and knowing when to seek medical advice can help patients manage their treatment effectively and identify any underlying issues requiring attention.

Does Rybelsus Make Your Urine Smell?

Rybelsus (semaglutide) is an oral medication used to manage type 2 diabetes by mimicking the action of glucagon-like peptide-1 (GLP-1), a naturally occurring hormone that regulates blood glucose levels. Whilst Rybelsus is generally well-tolerated, patients occasionally report changes in urine odour during treatment. However, there is no official link established between Rybelsus and alterations in urine smell in the product's Summary of Product Characteristics (SmPC) or European Medicines Agency (EMA) assessment reports.

It is important to recognise that changes in urine odour can arise from multiple factors unrelated to the medication itself. These include dietary choices (such as asparagus, coffee, or certain spices), hydration status, urinary tract infections (UTIs), or metabolic changes associated with diabetes. In people with diabetes, changes in blood glucose management may theoretically affect urine characteristics, though this is not well-documented.

Dehydration is a particularly relevant consideration, as Rybelsus can cause gastrointestinal side effects such as nausea, vomiting, or diarrhoea—especially during the initial weeks of treatment. These symptoms may lead to reduced fluid intake or increased fluid loss, resulting in more concentrated urine with a stronger odour. Additionally, some patients may experience changes in appetite or dietary patterns whilst taking Rybelsus, which could indirectly influence urine smell.

Other medications commonly prescribed alongside Rybelsus, such as SGLT2 inhibitors, can increase glucose in the urine and raise the risk of UTIs, potentially contributing to urine odour changes independently.

If you notice persistent or unusual changes in your urine odour whilst taking Rybelsus, it is advisable to discuss this with your GP or diabetes specialist. They can assess whether the change is related to the medication, your diabetes management, or another underlying cause requiring investigation.

Why Urine Odour Changes Can Occur with Rybelsus

Understanding the potential mechanisms behind urine odour changes can help patients and healthcare professionals identify the underlying cause. Rybelsus works by activating GLP-1 receptors, which stimulates insulin secretion in a glucose-dependent manner, suppresses glucagon release, slows gastric emptying, and reduces appetite. These actions collectively improve glycaemic control but can also trigger side effects that indirectly affect urine characteristics.

One of the most common reasons for altered urine odour in patients taking Rybelsus is dehydration secondary to gastrointestinal side effects. Nausea, vomiting, and diarrhoea—which vary in frequency depending on dose and individual response—can lead to fluid depletion. When the body becomes dehydrated, urine becomes more concentrated, intensifying its natural odour. This is a physiological response rather than a direct drug effect.

Dietary modifications often accompany Rybelsus treatment, as the medication's appetite-suppressing effects may lead patients to alter their eating patterns. Changes in protein intake, consumption of certain vegetables (such as asparagus or Brussels sprouts), or increased coffee intake can all contribute to noticeable changes in urine smell. Furthermore, some patients may adopt ketogenic or low-carbohydrate diets to enhance weight loss, which can produce ketones that impart a distinctive, sometimes sweet or fruity odour to urine. If considering substantial dietary changes, it's important to discuss these with your diabetes care team first.

Improved glycaemic control itself may play a role. As blood glucose levels normalise with Rybelsus treatment, the composition of urine may change. Additionally, urinary tract infections—which are not directly caused by GLP-1 receptor agonists like Rybelsus but may occur coincidentally—can produce a strong, unpleasant smell and should always be considered when evaluating new urinary symptoms.

When to Seek Medical Advice About Urine Changes

Whilst mild changes in urine odour are often benign and related to hydration or diet, certain accompanying symptoms warrant prompt medical evaluation. You should contact your GP or diabetes care team if you experience:

• Strong, foul-smelling urine accompanied by pain or burning during urination, increased urinary frequency, or lower abdominal discomfort—these may indicate a urinary tract infection requiring antibiotic treatment according to NICE guidance (NG109).

• Sweet or fruity-smelling urine alongside excessive thirst, frequent urination, fatigue, nausea, or confusion—these could be signs of diabetic ketoacidosis (DKA), a serious complication requiring urgent medical attention. Although DKA is rare with type 2 diabetes and GLP-1 receptor agonists, it remains a medical emergency. Call 999 or go to A&E immediately if you suspect DKA.

• Dark or concentrated urine persisting despite adequate fluid intake, especially if accompanied by dizziness, dry mouth, or reduced urine output—these may suggest significant dehydration.

• Blood in the urine (haematuria) or cloudy urine with sediment, which could indicate infection, kidney stones, or other urological conditions. Visible blood in urine may require urgent referral under NICE suspected cancer guidelines (NG12).

NICE guidance for type 2 diabetes (NG28) recommends that patients maintain regular monitoring of their overall health, including urinary symptoms. If you develop new or persistent urinary changes whilst taking Rybelsus, your healthcare provider may arrange a urine dipstick test to check for infection, glucose, ketones, protein, or blood. Further investigations such as urine culture, blood tests (including renal function and HbA1c), or imaging may be warranted depending on clinical findings.

It is particularly important not to dismiss urinary symptoms in the context of diabetes, as people with diabetes have an increased risk of urinary tract infections and other complications. Early identification and treatment can prevent more serious health issues.

Other Side Effects of Rybelsus to Be Aware Of

Beyond potential urinary changes, Rybelsus is associated with a range of side effects that patients should recognise. The most frequently reported adverse effects are gastrointestinal in nature, particularly during the initial weeks of treatment and following dose increases. According to the SmPC, these include:

• Nausea—usually mild to moderate and often diminishing over time

• Vomiting and diarrhoea—which can contribute to dehydration if not managed appropriately

• Abdominal pain and decreased appetite—reflecting the medication's effect on gastric emptying and satiety signals

• Constipation—affecting some patients, particularly those with reduced food and fluid intake

Severe gastrointestinal symptoms can lead to dehydration, which may precipitate acute kidney injury in some patients. If you experience persistent vomiting or diarrhoea, contact your healthcare provider, as monitoring of renal function may be necessary.

To minimise gastrointestinal side effects, Rybelsus should be taken on an empty stomach with no more than 120ml of water, at least 30 minutes before food, drink, or other medications. The tablet should be swallowed whole and not split, crushed or chewed. Patients should start with the 3mg dose for one month (for initiation only, not for glycaemic control), before escalating to 7mg, with a further increase to 14mg if additional glycaemic control is needed.

Less common but important side effects include:

• Hypoglycaemia—particularly when Rybelsus is used in combination with insulin or sulphonylureas; dose adjustments of these medications may be necessary

• Acute pancreatitis—rare but serious; patients should seek immediate medical attention if they develop severe, persistent abdominal pain radiating to the back

• Gallbladder disorders—including cholelithiasis (gallstones) and cholecystitis

• Changes in vision—temporary worsening of diabetic retinopathy has been reported with rapid improvement in glycaemic control

The SmPC includes a precautionary warning about thyroid C-cell tumours based on animal studies, though the risk in humans remains unproven. The only contraindication listed in the UK SmPC is hypersensitivity to semaglutide or any of the excipients.

If you experience any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at yellowcard.mhra.gov.uk.

Managing Side Effects While Taking Rybelsus

Effective management of side effects can significantly improve treatment adherence and outcomes with Rybelsus. For gastrointestinal symptoms, which are the most common reason for treatment discontinuation, consider the following strategies:

Dietary modifications can be particularly helpful. Eating smaller, more frequent meals rather than large portions may reduce nausea and abdominal discomfort. Avoiding fatty, spicy, or heavily seasoned foods during the initial treatment period can also minimise gastrointestinal upset. Some patients find that bland foods such as toast, crackers, or rice are better tolerated when nausea is prominent.

Adequate hydration is essential, especially if you experience vomiting or diarrhoea. Aim to drink at least 1.5–2 litres of water daily, adjusting for activity level and climate. If you have heart or kidney disease, follow your healthcare professional's guidance on fluid intake. If plain water is unappealing due to nausea, try small sips throughout the day or consider sugar-free electrolyte solutions. Proper hydration will also help prevent concentrated urine and associated odour changes.

Timing and administration are critical for Rybelsus efficacy and tolerability. Take the tablet first thing in the morning on an empty stomach with no more than 120ml of water. Swallow the tablet whole—do not split, crush or chew it. Wait at least 30 minutes before eating, drinking, or taking other medications. This ensures optimal absorption and may help reduce gastrointestinal side effects.

Gradual dose escalation, as recommended in the prescribing information, allows your body to adjust to the medication. The 3mg dose is for initiation only and not intended for glycaemic control. Remain on 3mg for the full month before moving to 7mg, even if side effects are minimal.

Communication with your healthcare team is vital. If side effects are severe or persistent beyond the first few weeks, your GP or diabetes specialist may suggest:

• Temporary dose reduction

• Anti-emetic medication for nausea

• Review of concomitant diabetes medications to reduce hypoglycaemia risk

• Alternative GLP-1 receptor agonist formulations if oral semaglutide remains poorly tolerated

According to NICE guidelines (NG28), treatment decisions should be individualised based on efficacy, tolerability, patient preference, and cost-effectiveness. Regular follow-up appointments allow monitoring of HbA1c, weight, renal function, and overall treatment response, ensuring that Rybelsus continues to provide benefit whilst minimising adverse effects.

Frequently Asked Questions